Deliver Your News to the World

CybeRelease: (OTC: TTGL) Offers Transcript of Investor Conference Call


(CybeRelease, January 24, 2007) - Lake Harmony, PA - Titan Global Holdings, Inc. (OTC BB: TTGL), a high-growth diversified holding company, invites investors to view a transcript of the Company’s recent investor conference call, during which President and Chief Executive Officer Bryan Chance detailed ongoing initiatives and other progress to address high-growth revenue opportunities through the Company’s telecommunications and technology subsidiaries.

During the conference call, Mr. Chance highlighted key elements of Titan’s strategy to capitalize on the global convergence of communications and other worldwide markets. Among other updates, he discussed Titan’s recently reported quarterly report for fiscal Q1 2007 with revenues topping $29.9 million, representing a $2.3 million gain over the same period the previous year.

“Our highly proactive and seasoned management team is focused on expanding organic growth and growth through acquisitions,” said Mr. Chance. “We feel very confident that Titan’s Q1 success will carry forward well into fiscal 2007. We continue to make strategic moves that we believe are essential to building shareholder value.”

To read the full text of the recent conference call, please visit
To read the complete release, go to .

For a Free Newsletter and more information, go to

CybeRelease Gainers are Nutrition 21 Inc. (Nasdaq: NXXI), Mindspeed Technologies, Inc. (Nasdaq: MSPD), Nitches, Inc. (Nasdaq: NICH), Neurocrine Biosciences, Inc. (Nasdaq: NBIX), Northfield Laboratories Inc. (Nasdaq: NFLD), Movie Gallery, Inc. (Nasdaq: MOVI), Pan American Silver Corp. (Nasdaq: PAAS) and DayStar Technologies, Inc. (Nasdaq: DSTI).

CybeRelease Decliners are UAL Corporation (Nasdaq: UAUA), Nektar Therapeutics (Nasdaq: NKTR), Radiation Therapy Services, Inc. (Nasdaq: RTSX), Phase Forward Incorporated (Nasdaq: PFWD), Discovery Laboratories, Inc. (Nasdaq: DSCO), deCODE genetics, Inc. (Nasdaq: DCGN), Immunomedics, Inc. (Nasdaq: IMMU) and, Inc. (Nasdaq: OSTK).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.